Odonate Therapeutics™
Pharmaceutical ManufacturingView the employees at
Odonate Therapeutics™-
Arun Vishwakarma Site Director of Clinical Operations
-
Greater Melbourne Area
-
Rising Star
Wen Lee Site Director at Odonate Therapeutics™-
Las Vegas, Nevada, United States
-
Rising Star
Yi Fei Lay Site Director, Clinical Operations at Odonate Therapeutics™-
Singapore
-
Rising Star
Faith Bumpus Site Director at Odonate Therapeutics™-
Paris, Tennessee, United States
-
Top 5%
stephanie daniels-lopez Site Director at Odonate Therapeutics™-
Odessa, Floride, États-Unis
-
Rising Star
Overview
Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent belonging to a class of drugs known as taxanes, which are widely used in the treatment of cancer. In December 2017, Odonate initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
-